BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
Hepatitis B clinical trials and catalysts
Active industry-sponsored trials on ClinicalTrials.gov for hepatitis B: 93 (51 sponsors; 27 newly posted in the last 180 days, 2 stopped in the last 180 days; 8 new-entrant sponsors). Momentum score 24.7, rank 13 of 91 on the disease-area ranking. As of 2026-11-18.
Phase distribution: Early Phase 1 2, Phase 1 25, Phase 2 38, Phase 3 16, Phase 4 2, N/A 10.
Most active sponsors, by phase
| Sponsor | Active trials | By phase | New (window) | Upcoming readouts |
|---|---|---|---|---|
| Fujian Akeylink Biotechnology Co., Ltd. | 5 | P3 2, P2 2, P1 1 | 2 | 2 |
| Beijing Continent Pharmaceutical Co, Ltd. | 2 | P3 2 | 0 | 0 |
| PT Bio Farma | 2 | P3 2 | 1 | 1 |
| Ausper Biopharma Co., Ltd. | 12 | P3 1, P1 3, P2 7, NA 1 | 5 | 3 |
| Grand Theravac Life Sciences (Nanjing) Co., Ltd. | 5 | P3 1, EARLY_P1 1, P2 2, P1 1 | 1 | 1 |
| Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 3 | P2 2, P3 1 | 1 | 0 |
| Fujian Shengdi Pharmaceutical Co., Ltd. | 2 | P2 1, P3 1 | 1 | 0 |
| Gilead Sciences GILD | 2 | P3 1, P2 1 | 0 | 0 |
| GC Biopharma Corp | 1 | P3 1 | 0 | 0 |
| LG Chem | 1 | P3 1 | 0 | 0 |
| Sanofi SNY new entrant | 1 | P3 1 | 1 | 0 |
| Shanghai Zhimeng Biopharma, Inc. | 1 | P3 1 | 0 | 0 |
| Tanabe Pharma Corporation new entrant | 1 | P3 1 | 1 | 0 |
| GlaxoSmithKline | 6 | P4 1, P1 2, P2 3 | 2 | 2 |
| Xiamen Amoytop Biotech Co., Ltd. | 5 | NA 1, P1 4 | 3 | 4 |
| AusperBio Therapeutics Inc. | 3 | P1 1, P2 2 | 2 | 1 |
| Suzhou HepaThera Biotech Co., Ltd. | 3 | P2 3 | 1 | 1 |
| bioLytical Laboratories | 2 | NA 2 | 0 | 2 |
| Epigenic Therapeutics, Inc | 2 | P1 1, EARLY_P1 1 | 0 | 1 |
| Lion TCR Pte. Ltd. | 2 | P2 1, P1 1 | 0 | 1 |
| Precision BioSciences, Inc. DTIL | 2 | NA 1, P1 1 | 0 | 1 |
| Aligos Therapeutics ALGS | 1 | P2 1 | 0 | 1 |
| Arbutus Biopharma Corporation ABUS | 1 | NA 1 | 0 | 0 |
| Asia Cell Therapeutics (Shanghai) Co., Ltd. | 1 | P2 1 | 0 | 1 |
| Beijing Tuohua Weiye Biotechnology Co., Ltd. | 1 | P2 1 | 0 | 1 |
New-entrant sponsors: Sanofi, Tanabe Pharma Corporation.
Recently stopped trials
- NCT05330455 GlaxoSmithKline - terminated: The study was terminated as a strategic decision Study of GSK3965193 in Healthy Participants and Participants Living With Chronic Hepatitis B Infection
- NCT06082336 MagIA Diagnostics - terminated: Liquidation of MagIA Diagnostics Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screEN
Upcoming trial readouts (next 90 days)
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-12-01 est. | P3 | Fujian Akeylink Biotechnology Co., Ltd. | NCT07090759 To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Anti | Chronic Hepatitis b | recruiting | 526 |
| 2026-12-12 est. | P2 | Ausper Biopharma Co., Ltd. | NCT07137910 A Study to Evaluate the Efficacy and Safety of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | recruiting | 200 |
| 2026-12-18 est. | P3 | Ausper Biopharma Co., Ltd. | NCT07246889 Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE) | Chronic Hepatitis B | active not recruiting | 577 |
| 2026-12-31 est. | P1/P2 | Beijing Tuohua Weiye Biotechnology Co., Ltd. | NCT07413549 Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis | Decompensated Hepatitis B Cirrhosis | recruiting | 76 |
| 2027-02 est. | P2 | Suzhou HepaThera Biotech Co., Ltd. | NCT07245953 A Clinical Study of HT-101 and HT-102 in Patients With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | active not recruiting | 60 |
Readouts in the last 180 days
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|---|---|---|---|---|---|
| 2026-10-27 | P2 | Gilead Sciences GILD | NCT02932150 Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection | Chronic Hepatitis B | active not recruiting | 150 |
| 2026-10-01 est. | P2 | Fujian Akeylink Biotechnology Co., Ltd. | NCT07709520 Study of GST-HG131&141 Tablets Compared With Placebo in Patients With Chronic Hepatitis B | Chronic Hepatitis B | recruiting | 80 |
| 2026-09 est. | P1/P2 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | NCT06452693 A Clinical Study to Evaluate the Efficacy of TQA3038 Injection in Patients With Chronic Hepatitis B | Hepatitis B, Chronic | unknown | 162 |
| 2026-08-30 est. | P2 | Fujian Shengdi Pharmaceutical Co., Ltd. | NCT06425341 A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injection Alone or in Combination With Other Agents in | Chronic Hepatitis B | recruiting | 369 |
| 2026-08-05 | P2 | Brii Biosciences Limited | NCT06491563 Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNα Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH) | For Treatment of Chronic Hepatitis B Virus Infection | completed | 150 |
| 2026-08-02 est. | P2 | Ausper Biopharma Co., Ltd. | NCT06829329 Study to Evaluate the Efficacy and Safety of AHB-137 in Treatment-naive Participants With Chronic Hepatitis B (CHB) | Chronic Hepatitis B | active not recruiting | 105 |
| 2026-07-28 | P3 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07343778 A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis | Chronic Hepatitis B With Hepatic Fibrosis | completed | 337 |
| 2026-07-27 | P2 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07417553 A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis | Chronic Hepatitis B-related Liver Fibrosis | completed | 67 |
| 2026-06-30 est. | P3 | GC Biopharma Corp | NCT05686759 A Study to Investigate the Safety and Efficacy of Undiluted Intravenous Infusion of I.V.-Hepabig Inj. | Hepatitis B | recruiting | 105 |
| 2026-06-22 | P2 | Beijing Continent Pharmaceutical Co, Ltd. | NCT07364448 A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis | Chronic Hepatitis B With Hepatic Fibrosis | completed | 411 |
| 2026-06-07 est. | P2 | Shanghai Argo Biopharmaceutical Co., Ltd. | NCT07135349 A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B | Chronic Hepatitis B | active not recruiting | 209 |
Landscape counts: ClinicalTrials.gov, industry lead sponsors, active statuses, via the free hosted BioCatalystFeed MCP tool condition_landscape (query "hepatitis B"); readouts matched by condition text. Registry counts only; not a forecast.
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.